Clinical trials
B Lymphoblastic Lymphoma clinical trials
Below are recruiting b lymphoblastic lymphoma clinical trials, each written for real people, not researchers. We’re tracking 138 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06785818Recruiting
Long-term follow-up of Kymriah patients in South Korea
This study follows patients in South Korea who have already received Kymriah (tisagenlecleucel) in a real-world setting. It aims to monitor their long-term health and any side effects over time.
Bundang Gu, Gyeonggi-doAges birth–100 years - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
Los Angeles, CaliforniaAges 6 months–25 years - NCT04195633RecruitingPhase 2
Haploidentical donor stem cell transplant to treat blood cancers
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
Seattle, WashingtonAges 6 months+ - NCT06445803RecruitingPhase 1
CAR-T therapy for adults with certain blood cancers
This trial tests a type of immunotherapy called CAR-T cells that target two proteins (CD19 and CD22) on cancer cells. It may be an option for adults with B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) that has come back or not responded to earlier treatments.
Nanchang, JiangxiAges 18 years+ - NCT03226704Enrolling by invitation
Leukapheresis to prepare CAR cell therapy
This trial collects white blood cells through a procedure called leukapheresis to help make CAR or other adoptive cell therapies. It’s for people with certain cancers who are not in remission (or are at high risk of relapse) and can meet health and lab requirements.
Bethesda, MarylandAges 3–65 - NCT06866873Recruiting
CAR-T cell therapy for kids with ALL or lymphoma
This trial tests a special immune cell treatment (CAR-T cells) for children whose leukemia or lymphoma has come back or not responded to at least two prior treatments. The goal is to see if these cells can find and destroy the cancer.
Hong KongAges 1–17 - NCT06961669Recruiting
CD19 CAR-T cells for B-cell cancers and multiple myeloma
This trial tests a personalized treatment where your own immune cells are modified to target and kill cancer cells that have a protein called CD19. It is for patients with certain types of B-cell lymphoma, B-cell acute leukemia, or multiple myeloma that has come back or not responded to previous treatment.
HefeiAges 3 years+ - NCT06060782RecruitingPhase 1
Chemo combo for high-risk blood cancer transplant patients
This trial tests a combination of drugs (thiotepa, cyclophosphamide, clarithromycin, and cytarabine) before a stem cell transplant. It is for people with certain types of blood cancer who have responded well to earlier treatment.
Zhuhai, GuangdongAges 18–65 - NCT04546399RecruitingPhase 2
Blinatumomab with or without nivolumab for first relapse ALL
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
Birmingham, AlabamaAges 1–30 - NCT04544592RecruitingPhase 1/Phase 2
CD19 CAR-T for children and young adults with B-cell blood cancers
This trial tests a one-time, lab-made immune cell treatment (CD19 CAR-T) for certain B-cell blood cancers in children and young adults. It may help people whose leukemia or lymphoma is not responding to standard treatment or has come back.
Aurora, ColoradoAges 1 month–30 years - NCT06593145RecruitingPhase 1
CAR-T therapy for relapsed CD19+ B-cell cancers
This trial tests a new type of CAR-T cell therapy for people with certain B-cell cancers (leukemia or lymphoma) that have not responded to standard treatments. It aims to see if these specially engineered immune cells can attack and destroy the cancer.
Warsaw, Ul. Banacha 1aAges 18–65 - NCT04993690RecruitingPhase 1
Oral LP-168 for relapsed or hard-to-treat B-cell lymphoma
This Phase 1 study tests whether an oral medicine called LP-168 can be given safely and possibly work against lymphoma that has come back or is not responding to standard treatment. It’s mainly looking for safety, but your results could help determine whether the drug should be studied further.
Beijing, Beijing MunicipalityAges 18–80 - NCT07205315RecruitingEarly Phase 1
Testing GT801 cell therapy for blood cancer and AIHA
This study tests an investigational cell therapy called GT801 for people whose CD19-positive blood cancer (B-ALL, CLL, or B-NHL) or autoimmune hemolytic anemia (AIHA) has not responded to standard treatments. The therapy is made from your own immune cells, modified to target and destroy cancer cells or abnormal immune cells.
Zhengzhou, HenanAges 18–75 - NCT02727803RecruitingPhase 2
Personalized natural killer cell therapy for blood cancers
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Houston, TexasAges 15–80 - NCT06879340RecruitingPhase 1
Testing a new CAR-T therapy for B-cell blood cancers
This study tests a new CAR-T cell therapy called DuoCAR20.19.22-D95 for people with certain blood cancers (like lymphoma and ALL) that have come back or haven't responded to multiple treatments. It aims to see if this therapy is safe and can help shrink or control the cancer.
Westwood, KansasAges 18 years+ - NCT06880913RecruitingPhase 1/Phase 2
Dual CAR-T therapy for relapsed B-cell acute lymphoblastic leukemia
This trial tests a new type of CAR-T cell therapy that targets two markers (CD19 and CD22) on leukemia cells. It's for people whose B-cell acute lymphoblastic leukemia has come back or hasn't responded to other treatments.
Beijing, Beijing MunicipalityAges 12–65 - NCT04532268RecruitingEarly Phase 1
CD19 CAR-T for relapsed or resistant B-cell blood cancers
This early-phase study tests “humanized” CD19 CAR-T therapy for people whose B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoma (NHL) has come back or didn’t respond. It’s designed to help the immune system recognize and attack cancer cells carrying the CD19 marker.
Hangzhou, ZhejiangAges 3–75 - NCT07513129RecruitingPhase 1
New drug combination for relapsed T-cell blood cancer in teens and young adults
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
Houston, TexasAges 12–30 - NCT07564453RecruitingPhase 2
Immunotherapy plus chemotherapy for newly diagnosed B-cell leukemia
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
Suzhou, JiangsuAges 15–65 - NCT04094311RecruitingPhase 3
Testing a modified cell therapy when product quality is off-spec
This study looks at using tisagenlecleucel, a cell therapy, when the final product does not meet routine “commercial release” quality standards. It focuses on whether it can still be given safely and effectively to people with serious or life-threatening illness.
Hamilton, OntarioAges birth–100 years - NCT07239323RecruitingPhase 1
CAR-T therapy for blood cancers that have returned or not responded
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
Kunming, YunnanAges 18 years+ - NCT05054257RecruitingPhase 1
CAR T19 for hard-to-treat blood cancers that have CD19
This Phase 1 study tests CAR T cells designed to attack cancer cells that carry a marker called CD19. It’s for adults with certain relapsed or treatment-resistant B-cell leukemias (ALL) or lymphomas (NHL) where other treatments may not have worked.
PragueAges 18–80 - NCT07109219RecruitingPhase 1/Phase 2
Study of AZD4512 for adults and teens with relapsed B-ALL
This trial tests a new drug called AZD4512, alone or with other cancer drugs, for people whose B-ALL has come back or did not respond to treatment. It may be an option if you have tried at least 2 prior therapies or have no standard options left.
Duarte, CaliforniaAges 12 years+ - NCT06350994Recruiting
Early Heart Check After CAR-T Cell Treatment
This study checks your heart function early after CAR-T cell cancer treatment. It uses a quick heart ultrasound to look for changes soon after the infusion.
ParisAges 18 years+
Hear when a new B Lymphoblastic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for b lymphoblastic lymphoma?
- Yes. Clin2 currently lists 138 recruiting b lymphoblastic lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a b lymphoblastic lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a b lymphoblastic lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.